stable psoriasis
Conditions
Interventions
Intervention group:PSORI-CMO1 granules+ Calcipotriol Betamethasone and C
Control group:PSORI-CMO1 decoction+ Calcipotriol Betamethasone and
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1)18 to 65 years old, male or female patient; (2)stationary stage, PASI more than 10 or BSA more than 10, meanwhile PASI less than 30 and BSA less than 30; (4)Informed consent.
Exclusion criteria
Exclusion criteria: (1)Guttate psoriasis, inverse psoriasis or exclusively involves the face; (2)Pregnant, lactating, or which one plan to become pregnant in a year; (3)SAS more than 50 or SDS more than 53, or with other psychiatric disorders; (4)With history of cardiovascular, respiratory, digestive, urinary, and hematologic disease, which can't controlled through common treatment. Either with cancer, infection, electrolyte imbalance, acid-base disturbance and calcium metabolic disorder; (5)Allergic to any medicine or ingredients used in this study; (6)Participating other clinical trials or participated within 1 month; (7)Topical treatments (i.e. corticosteroids, Retinoic acid) within 2 weeks; systemic therapy or phototherapy (UVB and PUVA) within 4 weeks; biological therapy within 12 weeks; (8)Acute progression of psoriasis, and erythroderma tendency; (9)Patients need systemic treatment prescribed by doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| recurernce rate;PASI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Onset time;Rebound rate;Ointment dosage;Visual Analogue Scale;DLQI;Relapse time interval;the Body Surface Area;the MOS item short form health survey; | — |
Countries
China
Contacts
Public ContactLu Chuanjian
Outcome results
None listed